Abstract:Increasing evidence has indicated the roles of sirtuin 7 (SIRT7) in numerous human cancers. However, the effects and the clinical significance of SIRT7 in human lung cancer is largely unknown. The present research demonstrated that SIRT7 was increased in human lung cancer tumor tissues. SIRT7 upregulation was associated with clinicopathological characteristics of lung cancer malignancy including positive lymph node metastasis, high pathologic stage and large tumor size. SIRT7 was also upregulated in human non-small cell lung cancer (NSCLC) cell lines. Furthermore SIRT7-overexpressed A549 (A549-SIRT7) and SIRT7-knocked down H292 (H292-shSIRT7) human NSCLC cell lines were established. Using these NSCLC cells and xenograft mouse models, it was revealed that SIRT7 overexpression markedly promoted growth and G1 to S cell cycle phase transition as well as migration, invasion and distant lung metastasis in A549 NSCLC cells, whereas SIRT7 knockdown suppressed these processes in H292 NSCLC cells. Mechanistically, in A549 NSCLC cells, SIRT7 overexpression significantly activated not only protein kinase B (AKT) signaling but also extracellular signal-regulated kinase 1/2 (ERK1/2) signaling. SIRT7 overexpression also significantly downregulated cyclin-dependent kinase (CDK) inhibitors including p21 and p27 as well as upregulated cyclins including cyclin D1 and cyclin E1, and CDKs including CDK2 and CDK4. Notably, the epithelial-mesenchymal transition (EMT) process of A549 NSCLC cells was facilitated by SIRT7 overexpression, as evidenced by E-cadherin epithelial marker downregulation and mesenchymal markers (N-cadherin, vimentin, Snail and Slug) upregulation. In addition, SIRT7 knockdown in H292 NSCLC cells exhibited the opposite regulatory effects. Moreover, inhibition of AKT signaling abated the promoting effects of SIRT7 in NSCLC cell proliferation and EMT progression. The present data indicated that SIRT7 accelerated human NSCLC cell growth and metastasis possibly by promotion of G1 to S-phase transition and EMT through modulation of the expression of G1-phase checkpoint molecules and EMT markers as well as activation of AKT and ERK1/2 signaling. SIRT7 could be an innovative potential target for human NSCLC therapy.

SIRT7 Depletion Inhibits Cell Proliferation, Migration, and Increases Drug Sensitivity by Activating P38mapk in Breast Cancer Cells

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

SIRT1 Facilitates Hepatocellular Carcinoma Metastasis by Promoting PGC-1α-mediated Mitochondrial Biogenesis.

SIRT7 Depletion Inhibits Cell Proliferation and Androgen-Induced Autophagy by Suppressing the AR Signaling in Prostate Cancer

SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells.

Sirtuin 7 Promotes Non-Small Cell Lung Cancer Progression by Facilitating G1/S Phase and Epithelial-Mesenchymal Transition and Activating AKT and ERK1/2 Signaling

SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer

SIRT7 sustains tumor development and radioresistance by repressing endoplasmic reticulum stress-induced apoptosis in cutaneous melanoma

SIRT7: a novel molecular target for personalized cancer treatment?

SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis

SIRT7 Promotes Mitochondrial Biogenesis to Render the Adaptive Resistance to MAPK Inhibition in Melanoma

Long noncoding RNA and mRNA profiling in MDA-MB-231 cells following RNAi-mediated knockdown of SIRT7.

SIRT7 Promotes Lung Cancer Progression by Destabilizing the Tumor Suppressor ARF

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

Blocking of SIRT7/FOXO3a Axis by miR-152-3p Enhances Cisplatin Sensitivity in Breast Cancer

Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer

Sirtuin 7 Promotes Glioma Proliferation and Invasion Through Activation of the ERK/STAT3 Signaling Pathway.

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.

791 Up-regulated SIRT7 Expression Contributed to Melanoma Growth by Promoting MITF Expression

Regulation of SIRT2 Levels for Human Non-Small Cell Lung Cancer Therapy.

SIRT7: A potential prognostic marker and therapeutic target in gallbladder cancer